Direct Healthcare Professional Communication (DHPC) on Noxafil (posaconazole): new dosage form – risk of medication error
2023.07.07
Active substance: posaconazole
Merck Sharp & Dohme, B.V in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you of a new formulation of Noxafil, gastro-resistant powder and solvent for oral suspension (PFS) has been approved for use in children 2 years of age and older. The newly available Noxafil PFS and the existing oral suspension (OS) formulation including generics are not interchangeable. Substitution between the two formulations can potentially result in over- or underdosing, and risks of serious adverse drug reactions or lack of efficacy.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN